CD274 and hepatocellular carcinoma: Toward this goal, we applied CRISPR-Cas9–based gene editing, deleted Pd-l1 in tumor cells, and tested whether ablation of PD-L1 in HCC cells recapitulated anti–PD-L1 activities during the combination therapy.